News Medical on MSN8d
FXR cyclic peptide antagonists as a novel strategy for MASH treatmentIn this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating ...
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...
Ready to save your liver? Transcription factors are paving the way for metabolic dysfunction-associated fatty liver disease ...
are nuclear receptors mainly expressed in the liver and intestine. FXR agonists are synthetic compounds thought to hold potential across several gastrointestinal (GI) diseases. However ...
Several transcription factors, including farnesoid X receptor (FXR), peroxisome proliferator-activated receptors (PPARs), thyroid hormone receptors (THRs), and liver X receptors (LXRs), have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback